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Survival at 10 years following lower extremity amputations in patients with 
diabetic foot disease.  
Abstract 
Background Amputations are associated with markedly reduced long-term survival in 
patients with diabetic foot disease. However, there is paucity of long-term survival 
data in published literature. 
Methods We searched the electronic case records and laboratory details of patients 
who underwent amputations between 1997 and 2006 to obtain at least 10 years of 
follow up data after the surgery to assess the survival rates and possible risk factors 
reducing survival in the year 2016. Amputation level below ankle was considered as 
minor and above ankle as major amputations. 
Results Of the 233 cases (159 males; median age 68 years), 161 had major 
amputations. Of the 72 cases who had minor amputations initially, 63 needed a further 
amputation or contralateral amputation on follow up. One hundred seventy-seven 
patients (76%) were not alive after 10 years of follow up. The survival rates at 1, 3, 5, 
7, and ≥10 years were 64%, 50%, 40%, 34%, and 24%, respectively. Maximum 
number of deaths occurred within 4 months of amputations. There was no difference 
between survival rates following major or minor amputations and among males or 
females. The only statistically significant parameter affecting lower survival rate was 
age ≥70 years, with each additional year of age increasing the hazard by a factor of 
1.039 (95% CI: 1.024–1.054) or 3.9% (2.4–5.4%). 
Conclusions Five-year and 10-year survival rates were 40% and 24%, respectively, 
following diabetic foot amputations. Higher age ≥70 years was associated with lower 
survival rate compared with younger age groups after lower extremity amputations. 
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Introduction 
Diabetes mellitus (DM) increases the risk of foot ulceration with 6% of patients 
having a diabetic foot ulcer (DFU) at any point of time 1, and 19–34% of diabetic 
patients likely to develop a foot ulceration in their lifetime 2, with high recurrence 
rates, and marked reduction of short-term and long-term survival in affected 
individuals 3. As a consequence of DFUs, many patients would require lower 
extremity/digital amputations. Compared with the nondiabetic populations, DM cases 
have ~30 times greater lifetime risk of amputations that substantially increase the 
economic burden of global healthcare systems 4, 5. Currently, DM is also established 
as the leading cause of lower extremity amputations 6. Recurrence rate of DFU is 
high, and more than 50% of patients with DFUs will have an amputation in their 
lifetime 7. The total healthcare expenditure related to DFUs and amputations in 
England alone between 2010 and 2011 was estimated at £. 580.5 million 8. This 
expenditure is expected to increase further in future owing to the steady increase in 
the incidence of DM. 
 
Both DFUs and DFU-related amputations greatly reduce the survival rates in patients. 
The reported 30-day survival rate following DFU-related amputations was 93.7 – 
79.7% in a recent multinational cohort study.9 The survival rate following lower 
extremity amputations decreases steadily over time. The unadjusted 5-year and 10-
year survival rates were 61% and 33% respectively in a previous study10 which were 
lower than the corresponding survival rates for those with breast cancer (90% and 
83% respectively)11 and colorectal cancer (64% and 58% respectively).12  The risk 
factors associated with reduced survival rates after lower extremity amputations were 
above-knee amputations, post-operative cardiac complications, higher age, renal 
failure, male gender, Hispanics, and associated peripheral vascular disease.10,13,14 
Although diabetic foot disease and DFU-related lower extremity amputations are 
common problems in day-to-day clinical practice, there is paucity of long-term 
follow-up survival data after foot-amputations in the global scientific literature. 
Therefore, we report the results of a 10-year follow-up survival data after lower 
extremity amputations from a regional tertiary care center in the UK. The study also 
investigated the possible risk factors associated with reduced survival after 
amputations and compared the survival rates following minor and major amputations. 
 
Materials and methods  
After obtaining approval from the audit department, a list of diabetic patients who had 
undergone amputations at the Lancashire teaching Hospitals NHS Trust, between 
1997 and 2006, were collected retrospectively in 2016 to allow a minimum follow-up 
period of at least ten years following the surgery. This Hospital Trust has 2 acute care 
hospitals (Chorley District Hospital and Royal Preston Hospital) with a total of 750 
inpatient beds. These two hospitals provide healthcare for a population of 300,000 
across Central Lancashire including comprehensive diabetic foot care. Patients from 
the neighboring district hospitals with diabetic foot disease are also often referred to 
this tertiary vascular center of this hospital Trust. These patients are then referred 
back to the referring hospitals after their surgery including amputations.  
The foot care team involves diabetologists, diabetes nurse specialists, podiatrists, 
orthotists, vascular surgeons, and orthopedic surgeons. Decisions regarding a foot 
amputation are based on this multi-disciplinary team plan for the optimal care of 
patients with diabetic foot disease.  
The clinical information, demographics (such as age and gender), and the laboratory 
data of patients treated during the above period were collected using the electronic 
databases (Evolve and Quadramed) of the hospital, and all the clinic letters were 
searched to gather full information about the care each patient received during and 
following the amputations. An amputation higher than the level of the ankle was 
regarded as a major amputation, whereas any amputation below the ankle was 
categorized as a minor amputation. All the relevant investigations to document 
anemia, renal impairment, albumin levels, glycated hemoglobin (HbA1c) and lipids at 
the time of amputations were collected. Type of operations in each patient, and 
presence/ absence of any cancer was assessed.  
 
Only hemoglobin levels after the amputation was considered because any source of 
infection present at the time of amputation could have possibly caused a drop in 
hemoglobin levels and would not necessarily mean that the patient was anemic. 
Normal reference hemoglobin values for men are 130–180 g/L and115–165 g/L for 
women. Renal impairment was assessed by recording creatinine levels, and values 
between 59–104 µmol/L were considered normal. Albumin levels recorded before 
and after the surgery were averaged, and values 35 – 50 g/L were considered normal. 
HbA1c levels of ≤ 7.5% in patients with co–morbidities were considered optimal 
control of DM. Cholesterol levels <5 mmol/L were regarded as normal while levels ≥ 
5 mmol/L were viewed as high. Those cases with insufficient follow up data and 
those from out of hospital catchment area whose current status could not be assessed 
were excluded from the study.  
 
Statistical analysis 
Descriptive categorial variables are shown as counts and percentages, whereas 
continuous variables are summarized using median and ranges (not normally 
distributed) or mean ± standard deviation (normally distributed). Welch’s t-tests were 
performed to investigate age differences between amputation type received and sex. 
We generated Kaplan–Meier estimators and curves to assess the influence of 
amputation, and type of amputation (major vs. minor), sex (female vs. male), and age 
(≥70 vs. < 70 years) on survival. Cox proportional hazard ratios were generated to 
assess whether age at amputation (univariate, model 1), and age at amputation, 
amputation type, sex, anemia, dyslipidemia, liver dysfunction, renal impairment, and 
poor glycemic control (model 2) influenced survival postamputation. The statistical 
significance level was set at p < 0.05, and we did not adjust for multiple comparisons. 
Statistical analysis was performed using Rstudio version 1.2.5019 (survival analysis 
and plots) and Jamovi version 1.1.7.0 (descriptive analysis and t-tests). 
 
Results  
Out of 387 cases that were retrieved from the electronic data search who had 
undergone amputations during the study period, 233 (60%) cases with sufficient 
follow up data were included in the analysis. Most patients were males (n = 159; 
68%), and the median age of patients was 69 years (range 29–95 years) with 111 
(48%) cases aged at least 70 years. Almost 58% of patients (n = 134) had major 
amputations and 99 had minor amputations. Out of these minor amputations, 63 cases 
needed a more proximal amputation or contralateral amputation subsequently and 
were still grouped as minor due to the index amputation status. There were no age 
differences between female and male patients (Welch’s t=0.83, p=.41) or by 
amputation type received (Welch’s t=1.59, p=.11).  
 
We recorded 177 (76% of patients) deaths during the study period (start January 
1997; end of follow up, June 2016). The median follow-up for all patients was 3 
(IQR=0–11) years, but was 14 (11–16) years for those alive at follow-up and 1.5 (0–
4) years for those who died. The greatest number of deaths (n = 84; 47.5% of all 
deaths) occurred within the first year following the amputation and most of these (n = 
63; 36.6% of all deaths) were within first 4 months of the surgery (Fig. 1). The 
survival rate over 10-year follow-up period was as follows: end of first year—64%, 3 
years—50%, 5 years—40%, 7 years—34%, 10 years—28%, and 10+ years—24%. 
Figure 2 shows the overall survival curve following amputations at 10+ years after the 
index surgery, and Table 1 shows long-term survival characteristics of the whole 
cohort. 
 
There was no statistically significant overall survival difference between major and 
minor surgery, with 116 (72% of patients) and 61 (69%) deaths reported after major 
and minor amputation, respectively [major vs. minor, median (interquartile range; 
IQR) years survival = 3 (2–4) years vs. 5 (3–7) years, Fig. 3]. Similarly, we observed 
similar survival for female and male patients throughout the study period, with 56 
(74%) deaths in female patients and second model with all covariates included, older 
age at amputation, again, statistically lowered survival, and having no renal 
impairment but having dyslipidemia statistically improved survival (Table 2). The p-
values for dyslipidemia and renal impairment, however, were just under the 0.05 
threshold and we did not adjust for multiple comparisons, therefore, there is a high 
risk these two findings may be false positives. The more complex model (model 2) 
provided only a slightly better fit (concordance index = 0.712 vs. 0.645 for model 1). 
 
Due to the retrospective design of the present study, a large proportion of cases had 
insufficient laboratory data for full assessment of comorbid illnesses and their 
influence on mortality. Only 122 (52%) cases each had data on renal impairment and 
liver dysfunction (albumin levels) at the time of amputations in the electronic records. 
Data on anemia, HbA1c, and dyslipidemia were available only in 121 (52%), 102 
(44%), and 99 (42%) cases respectively. Just 72 (31%) cases analyzed had all the 
parameters tested. Nine cases had cancer recorded in their clinical data although the 
influence of cancer on the mortality risk was unclear in the case records. Of those 
patients with relevant data, 89 (74%) had anemia, 28 (28%) had dyslipidemia, 59 
(48%) had liver dysfunction, 63 (52%) had renal impairment, and 55 (54%) had poor 
glycemic control (high HbA1C levels). 
 
Discussion  
Our retrospective study results provide a comprehensive picture on the survival rates 
among patients who underwent lower extremity amputations between 1997 and 2006 
that cover follow up period more than 10-year for a total of 233 patients as follows: 
patients alive at the end of one year – 64%, 3 years – 50%, 5 years – 40%, 7 years – 
34% and 10+ years – 24%. In our analysis, the only statistically significant parameter 
that affected survival was age at amputation 70 years or over. Each additional year of 
age after 70 years increased the hazard of death by a factor of 1.039 or 3.9%. 
 
There is wide discrepancy in the long-term survival rates among different cohorts of 
patients reported from various regions of the world owing to the study characteristics 
evaluated in the subjects studied.10,13, 15-18 For instance, we observed a 10+ year 
survival rate of 24% in our cohort, while McEwen. et al.10 and López-de-Andrés. et 
al.15 reported survival rates of 33% and 51.4% respectively in their studies. While we 
found a 5-year survival rate of 40%, that observed by McEwen. et al.,10 López-
Valverde. et al.,13 Gök. et al.,16 Huang. et al.,17 and Wilbek. et al.18 were 61%, 55.5%, 
30%, 40% and 58% respectively. Co-morbid disease states and cardiovascular factors 
inherent to diabetic foot disease might explain these wide discrepancies in the 
survival rates.    
 
The statistically significantly lower long-term survival rate we observed among the 
older subjects who underwent amputations in our study cohort had also been 
previously reported in other studies,13,17-19 although some other researchers did not 
find this association.15,17 Although we did not find any statistically significant 
difference between minor and major amputations on long-term survival, other 
workers reported lower survival rates associated with major amputations.10,16,17 Renal 
impairment4,13,19 male gender,10,19 and anemia20 were the risk factors associated with 
lower survival rates among patients who underwent diabetic foot amputations 
reported by other studies. Although renal impairment appeared to lower survival in 
our analysis, this observation was likely erroneous as mentioned above. We did not 
find any statistically significant effect of gender difference or anemia on survival rate 
in our cohort. We could not also find any statistically significant association of poor 
glycemic control on the mortality risk in this study population. 
 
We acknowledge that our study has several limitations. Because of the design (case 
note review), we could not obtain robust information about some of the laboratory 
variables for all the patients. This would have had an impact on the parameters we 
analyzed that might affect the survival. For example, although lack of renal 
impairment and cholesterol level above 5 mmol/l appeared to confer survival 
advantage in our analysis, these were very likely falsely positive. The cause of death 
could not be verified in most of the cases because of the lack of availability of the 
same in the hospital electronic data. A large proportion of cases (154 out of 387) who 
had amputations in the study period did not have follow up in the 2 hospitals where 
the study was conducted because their follow up were in the hospitals where they 
were referred from. Despite these limitations, our large cohort study gives valuable 
information regarding long-term survival data of diabetic foot amputations that should 




Diabetic lower extremity amputations were associated with a 5-year survival rate of 
40% and 10-year survival rate of 24%. Mortality rates were maximum in the first 4 
months after amputations. Higher age at amputation and hypoalbuminemia were 
associated with lower survival rates. Large multicenter long-term follow up studies 
are necessary to address the lack of adequate knowledge in survival trends following 
foot amputations.        
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Figure legends  
 
Figure 1. Cumulative monthly mortality of 84 patients who died within 12 months of 
amputations. 47.5% of all deaths occurred within 4 months of amputation surgery 
 
Figure 2: The Kaplan–Meier survival curve following lower extremity amputations 
over a 10+ year period among the whole amputation cohort 
 
 
Figure 3: Kaplan–Meier curve showing the survival among patients who underwent 
major and minor amputations on long-term follow up 
 
 
Figure 4. Kaplan–Meier curve showing the survival among patients ≥70 year those 
below 70 years who underwent lower extremity amputations on long-term follow up 
 
Table 1. Time-specific survival data among patients who underwent lower extremity 
amputations 
Year N at risk N of events Survival SE 95% CI 
1 233 80 0.66 0.032 0.60, 0.72 
3 134 37 0.50 0.033 0.44, 0.57 
5 102 20 0.41 0.032 0.35, 0.48 
7 86 17 0.34 0.031 0.28, 0.41 
9 75 7 0.31 0.030 0.26, 0.37 
11 66 6 0.28 0.030 0.23, 0.35 
13 45 1 0.27 0.030 0.23, 0.34 
15 28 0 0.27 0.030 0.23, 0.34 
20 2 0 0.27 0.030 0.23, 0.34 
 
Table 2 Multivariate analysis showing possible parameters affecting survival after 




SE p-value Hazard ratio 
(HR) 
95% CI for HR 
Age at amputation 0.039 0.014 0.005 1.040 1.012 to 1.069 
Amputation, minor vs. 
major 
-0.159 0.287 0.579 0.853 0.486 to 1.496 
Sex, male vs. female 0.002 0.365 0.996 1.002 0.490 to 2.069 
Anemia, no vs. yes -0.127 0.368 0.729 0.881 0.429 to 1.810 
Dyslipidemia, no vs. yes 0.705 0.344 0.041 2.023 1.031 to 3.970 
Liver dysfunction, no 
vs. yes 
-0.581 0.330 0.079 0.560 0.293 to 1.069 
Renal impairment, no 
vs. yes 
-0.591 0.292 0.043 0.554 0.312 to 0.981 
High HbA1C, no vs. yes 0.275 0.297 0.353 1.317 0.736 to 2.355 
Likelihood ratio = 23.64, df = 8, p = 0.003; n = 78, events = 54 (missing = 155). 
 
